Mostrar el registro sencillo del ítem

dc.contributor.authorde la Campa, Adela G 
dc.contributor.authorArdanuy, Carmen
dc.contributor.authorBalsalobre-Arenas, Maria Luz 
dc.contributor.authorPérez-Trallero, Emilio
dc.contributor.authorMarimón, Jose M
dc.contributor.authorFenoll, Asuncion 
dc.contributor.authorLiñares, Josefina
dc.date.accessioned2019-02-01T15:58:28Z
dc.date.available2019-02-01T15:58:28Z
dc.date.issued2009-06
dc.identifier.citationEmerg Infect Dis. 2009;15(6):905-11.es_ES
dc.identifier.issn1080-6040es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7068
dc.description.abstractAmong 4,215 Streptococcus pneumoniae isolates obtained in Spain during 2006, 98 (2.3%) were ciprofloxacin resistant (3.6% from adults and 0.14% from children). In comparison with findings from a 2002 study, global resistance remained stable. Low-level resistance (30 isolates with MIC 4-8 microg/mL) was caused by a reserpine-sensitive efflux phenotype (n = 4) or single topoisomerase IV (parC [n = 24] or parE [n = 1]) changes. One isolate did not show reserpine-sensitive efflux or mutations. High-level resistance (68 isolates with MIC >or=16 microg/mL) was caused by changes in gyrase (gyrA) and parC or parE. New changes in parC (S80P) and gyrA (S81V, E85G) were shown to be involved in resistance by genetic transformation. Although 49 genotypes were observed, clones Spain9V-ST156 and Sweden15A-ST63 accounted for 34.7% of drug-resistant isolates. In comparison with findings from the 2002 study, clones Spain14-ST17, Spain23F-ST81, and ST8819F decreased and 4 new genotypes (ST9710A, ST57016, ST43322, and ST71733) appeared in 2006.es_ES
dc.description.sponsorshipThis study was supported by grant BIO2008-02154 from Plan Nacional de I+D+I of Ministerio de Ciencia e Innovación and COMBACT-S-BIO-0260/2006 from Comunidad de Madrides_ES
dc.language.isoenges_ES
dc.publisherCenters for Disease Control and Prevention (CDC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult es_ES
dc.subject.meshAnti-Bacterial Agents es_ES
dc.subject.meshBacterial Proteins es_ES
dc.subject.meshChild es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshCiprofloxacin es_ES
dc.subject.meshDrug Resistance, Bacterial es_ES
dc.subject.meshElectrophoresis, Gel, Pulsed-Field es_ES
dc.subject.meshFluoroquinolones es_ES
dc.subject.meshGenotype es_ES
dc.subject.meshHeptavalent Pneumococcal Conjugate Vaccine es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMicrobial Sensitivity Tests es_ES
dc.subject.meshMutation es_ES
dc.subject.meshPneumococcal Vaccines es_ES
dc.subject.meshPrevalence es_ES
dc.subject.meshSequence Analysis, DNA es_ES
dc.subject.meshSerotyping es_ES
dc.subject.meshSpain es_ES
dc.subject.meshStreptococcal Infections es_ES
dc.subject.meshStreptococcus pneumoniae es_ES
dc.subject.meshTransformation, Bacteriales_ES
dc.subject.meshVaccination es_ES
dc.titleChanges in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spaines_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución- 4.0 Internacional*
dc.identifier.pubmedID19523289es_ES
dc.format.volume15es_ES
dc.format.number6es_ES
dc.format.page905-11es_ES
dc.identifier.doi10.3201/eid1506.080684es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.contributor.funderComunidad de Madrid (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1080-6059es_ES
dc.relation.publisherversionhttps://www.doi.org/10.3201/eid1506.080684es_ES
dc.identifier.journalEmerging infectious diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BIO2008-02154es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución- 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución- 4.0 Internacional